Search Results 171-180 of 10360 for cannabis

1. Esketamine (nasal route) - Mayo Clinic

   Cannabis; Carbamazepine; Carbidopa; Carbinoxamine; Carisoprodol; Carphenazine; Cetirizine; Chloral Hydrate; Chlordiazepoxide; Chlorpromazine; Chlorzoxazone ...

2. A Study to Evaluate the Effect of Olorinab on Gastrointestinal Transit in Patients with Irritable Bowel Syndrome - Mayo Clinic

   Medical or recreational marijuana, tetrahydrocannabinol (THC), cannabidiol (CBD), synthetic cannabinoids, or other cannabis derivatives for any indication; ...

3. A Study to Evaluate the Effectiveness, Safety, and Tolerability of BOS-589 in the Treatment of Patients with Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) - Mayo Clinic

   Cannabis-containing products;; Docusate;; Enemas;; GI preparations (including antacids containing aluminum or magnesium, antidiarrheal agents, antispasmodic ...

4. Effect of Cholecystokinin (CCK) on Gastroduodenal Activity in Humans - Mayo Clinic

   The purpose of this research study to compare the effects a hormone cholecystokinin (CCK) in the bloodstream in healthy people and in patients with rapid ...

5. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

   Subject who has concomitant cannabis use either recreational or for medical reasons within 14 days prior to Baseline or any history of clinically ...

6. Nalbuphine (injection route) - Mayo Clinic

   Cannabis; Carbamazepine; Carbidopa; Carbinoxamine; Carphenazine; Cetirizine; Chloral Hydrate; Chlordiazepoxide; Chlorpheniramine; Chlorpromazine; Chlorzoxazone ...

7. Spontaneous Coronary Artery Dissection: Case Review - Mayo Clinic

   About this study. Spontaneous coronary artery dissection (SCAD) is uncommon but important cause of acute coronary syndrome and sudden cardiac death.

8. A Study to Evaluate Safety and Effectiveness of SHP647 as Induction Therapy in Participants with Moderate-to- Severe Crohn's Disease - Mayo Clinic

   ... (cannabis). Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may ...

9. Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis - Mayo Clinic

   Active substance abuse (drugs, alcohol, or cannabis) or history of substance abuse within 12 months prior to Screening. Clinically significant abnormalities ...

10. Publications - Monica W. Harbell, M.D. - Mayo Clinic

    Cannabis for the Treatment of Fibromyalgia: A Systematic Review. Biomedicines. 2023 Jun 2; 11 (6) Epub 2023 June 02. View PubMed; Kraus MB, Leuzinger K ...